Clinical Trials Logo

Leukemia, Lymphoid clinical trials

View clinical trials related to Leukemia, Lymphoid.

Filter by:

NCT ID: NCT04204161 Recruiting - Clinical trials for Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood

A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma

Start date: October 8, 2019
Phase: Phase 1
Study type: Interventional

This is a single arm, open-label, uni-center, phase I study . In this study, Children withCD19+/CD22+ R/R B-cell acute lymphoblastic leukemia or lymphoma will be treated with CAR-T19/CAR-T22 Immunotherapy to determine the safety and efficacy of treatment.

NCT ID: NCT04196205 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia ,Lymphomas

Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas

Start date: December 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm, open-label, single center study to determine the safety and efficacy of Anti-CD19 CAR-T cells in patients with relapsed or refractory acute lymphoblastic leukemia and Lymphomas.

NCT ID: NCT04178317 Recruiting - Clinical trials for Cancer, Chronic Lymphocytic Leukemia (CLL)

A Study of the Safety and Efficacy of Venetoclax for Participants With Chronic Lymphocytic Leukemia (CLL) Used in Routine Clinical Practice

Start date: April 2, 2020
Phase:
Study type: Observational

This observational study will evaluate the safety and effectiveness of Venetoclax used in routine clinical practice for participants diagnosed with chronic lymphocytic leukemia (CLL).

NCT ID: NCT04169737 Recruiting - Clinical trials for Recurrent Small Lymphocytic Lymphoma

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Start date: July 29, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well acalabrutinib and venetoclax with or without early obinutuzumab work for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma that is high risk, has come back (recurrent), or does not respond to treatment (refractory). Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Venetoclax may stop the growth cancer cells by blocking BCL-2 protein needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving acalabrutinib and venetoclax together with early obinutuzumab may improve clinical outcomes and control the disease.

NCT ID: NCT04167683 Recruiting - Clinical trials for Acute Myeloid Leukemia

Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant

Start date: October 1, 2023
Phase:
Study type: Observational

PURPOSE: To investigate the effect of the disease and HSCT on muscle dysfunction and to investigate the prognostic role of muscle dysfunction at critical decision points in patients with hematological diseases referred to hematopoietic stem cell transplant (HSCT). HSCT: Patients diagnosed with malignant hematological diseases who are referred to myeloablative HSCT, to a myeloablative "reduced toxicity conditioning" regime with Fludarabine and Treosulfane (FluTreo) or to non-myeloablative HSCT.

NCT ID: NCT04166838 Recruiting - Clinical trials for B-cell Acute Lymphoblastic Leukemia (B-ALL)

The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL)

Start date: November 8, 2019
Phase: Early Phase 1
Study type: Interventional

This is a single arm, open-label, single center, exploratory clinical study to evaluate the safety and efficacy of CD19 UCAR-T Cells in Patients With CD19+ B-cell acute lymphoblastic leukemia (B-ALL).

NCT ID: NCT04154709 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia

Start date: December 10, 2019
Phase: Phase 1
Study type: Interventional

This study aims to evaluate the safety and feasibility of CTA101 in treating patients with relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia.

NCT ID: NCT04150497 Recruiting - Clinical trials for B-cell Acute Lymphoblastic Leukemia

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Start date: October 14, 2019
Phase: Phase 1
Study type: Interventional

This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate the safety and clinical activity of UCART22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

NCT ID: NCT04094311 Recruiting - Clinical trials for Diffuse Large B-cell Lymphoma

Study of Out of Specification for Tisagenlecleucel

Start date: November 21, 2019
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety of tisagenlecleucel that is out of specification( OOS) for release as commercial product. Specifically, this study will evaluate the safety of CTL019 in the patients treated within the approved label by Japan Health Authority in Part 2. Only for Part 1, in addition to safety, key efficacy of CTL019 will also be evaluated.

NCT ID: NCT04094051 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice

Start date: October 1, 2019
Phase:
Study type: Observational [Patient Registry]

This is a non-interventional, Phase 4 study designed to improve understanding of current clinical practice in the treatment of CLL/SLL and to describe treatment pattern and evaluate outcomes of ibrutinib-treated CLL patients in China. This study will include both retrospective and prospective data collection.